By Josh Beckerman

Liquidia Technologies Inc. (LQDA), which reached a broad, multiyear collaboration with GlaxoSmithKline (GSK) in 2012, has amended the agreement for development of products using Liquidia's PRINT technology.

The amended agreement gives Liquidia the right to develop and commercialize three additional PRINT-based therapeutics delivered via inhalation. Additionally, Liquidia can acquire rights to pursue additional PRINT-based programs, subject to GlaxoSmithKline approval.

Liquidia's lead product candidate is LIQ861, a dry powder formulation of treprostinil that is being evaluated for the treatment of pulmonary arterial hypertension. The company said Wednesday that submitting an LIQ861 New Drug Application is its top priority for 2019, but "we also see clear opportunities to further expand the Liquidia pipeline of respiratory products."

Liquidia's initial public offering was in July 2018.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

June 26, 2019 19:13 ET (23:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Gsk.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Gsk.